Journal Watch · Frontiers in Immunology · 2026

<i>HLA-DRB1*14</i> is associated with lower odds of symptomatic SARS-CoV-2 infection in Mexican individuals.

These data suggest that HLA-DRB1*14, a prevalent allele in the Mexican population, is associated with a reduced risk of symptomatic SARS-CoV-2 infection in this cohort.

Hernández EG, Daza-Mendoza DA, González-Rivas E et al.Frontiers in Immunology3 min readPharma relevance 30/100

DOI: 10.3389/fimmu.2026.1907153PMID: 42745975Study type: cohort / observational clinical study

TL;DR

These data suggest that HLA-DRB1*14, a prevalent allele in the Mexican population, is associated with a reduced risk of symptomatic SARS-CoV-2 infection in this cohort.

Key findings

  • The HLA-DRB1 locus was typed using NGS.
  • We found a significant increase in the frequency of the <i>HLA-DRB1*14</i> allele in the control group (OR = 0.37; 95% CI: 0.18-0.72; p = 0.003; pc = 0.03).
  • These data suggest that HLA-DRB1*14, a prevalent allele in the Mexican population, is associated with a reduced risk of symptomatic SARS-CoV-2 infection in this cohort.

Numbers at a glance (from the abstract)

n = 90n = 6095%p = 0.003

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Therefore, this pilot study analyzed the association between HLA-DRB1 genetic polymorphisms and the susceptibility and/or resistance to symptomatic SARS-CoV-2 infection in a population from the Metropolitan Area of the Valley of Mexico. Individuals with a confirmed SARS-CoV-2 infection were recruited (n = 90), as well as a seronegative control group without reported symptomatic infection (n = 60).

Full abstract (original)

Background: Mexico has been one of the countries most affected by the COVID-19 pandemic. Several factors can influence the susceptibility to SARS-CoV-2 infection, particularly highly polymorphic genes in the HLA system.

What they did: Therefore, this pilot study analyzed the association between HLA-DRB1 genetic polymorphisms and the susceptibility and/or resistance to symptomatic SARS-CoV-2 infection in a population from the Metropolitan Area of the Valley of Mexico. Individuals with a confirmed SARS-CoV-2 infection were recruited (n = 90), as well as a seronegative control group without reported symptomatic infection (n = 60).

Results & conclusions: The HLA-DRB1 locus was typed using NGS. We found a significant increase in the frequency of the <i>HLA-DRB1*14</i> allele in the control group (OR = 0.37; 95% CI: 0.18-0.72; p = 0.003; pc = 0.03). These data suggest that HLA-DRB1*14, a prevalent allele in the Mexican population, is associated with a reduced risk of symptomatic SARS-CoV-2 infection in this cohort.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1907153 · PubMed 42745975.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Frontiers in Immunology study find?

These data suggest that HLA-DRB1*14, a prevalent allele in the Mexican population, is associated with a reduced risk of symptomatic SARS-CoV-2 infection in this cohort.

What type of study is this?

It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. Therefore, this pilot study analyzed the association between HLA-DRB1 genetic polymorphisms and the susceptibility and/or resistance to symptomatic SARS-CoV-2 infection in a population from the Metropolitan Area of the Valley of Mexico.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1907153. PubMed ID: 42745975. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Hernández EG, Daza-Mendoza DA, González-Rivas E et al.. &lt;i&gt;HLA-DRB1*14&lt;/i&gt; is associated with lower odds of symptomatic SARS-CoV-2 infection in Mexican individuals.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1907153.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/lt-i-gt-hla-drb1-14-lt-i-gt-is-associated-with-lower-odds-of-symptomatic-907153/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides